W.P. Arnold | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where W.P. Arnold is active.

Explore More

Publication

Featured researches published by W.P. Arnold.

British Journal of Dermatology | 2014

'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

J.M.P.A. van den Reek; J. Zweegers; Wietske Kievit; M.E. Otero; P.P.M. van Lümig; R.J.B. Driessen; P.M. Ossenkoppele; M.D. Njoo; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; B.A.M. Sybrandy-Fleuren; A.L.A. Kuijpers; M.P.M. Andriessen; P.C.M. van de Kerkhof; M.M.B. Seyger; E.M.G.J. de Jong

Drug survival is a marker for treatment success. To date, no analyses relating dermatological quality‐of‐life measures to drug survival have been published.

British Journal of Dermatology | 2017

Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry

J. Zweegers; J.M.M. Groenewoud; J.M.P.A. van den Reek; M.E. Otero; P.C.M. van de Kerkhof; R.J.B. Driessen; P.P.M. van Lümig; M.D. Njoo; P.M. Ossenkoppele; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; M.P.M. Andriessen; A.L.A. Kuijpers; M.A.M. Berends; Wietske Kievit; E.M.G.J. de Jong

The efficacy of etanercept and ustekinumab in psoriasis has been compared in one randomized controlled trial. Comparison of the long‐term effectiveness of biologics in daily‐practice psoriasis treatment is currently lacking.

British Journal of Dermatology | 2016

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.

J. Zweegers; J.M.P.A. van den Reek; P.C.M. van de Kerkhof; M.E. Otero; A.L.A. Kuijpers; M.I.A. Koetsier; W.P. Arnold; M.A.M. Berends; L. Weppner-Parren; P.M. Ossenkoppele; M.D. Njoo; J.M. Mommers; P.P.M. van Lümig; R.J.B. Driessen; Wietske Kievit; E.M.G.J. de Jong

Predictors for successful treatment are important for personalized medicine. Predictors for drug survival of biologics in psoriasis have been assessed, but not split for different biologics or for the reason of discontinuation.

British Journal of Dermatology | 2014

Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE

J. Zweegers; J.M.P.A. van den Reek; P.C.M. van de Kerkhof; M.E. Otero; P.M. Ossenkoppele; M.D. Njoo; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; B.A.M. Sybrandy-Fleuren; A.L.A. Kuijpers; M.P.M. Andriessen; Wietske Kievit; E.M.G.J. de Jong

Treatment goals have been developed to optimize daily clinical practice psoriasis care, but have not yet been studied in real life.

British Journal of Dermatology | 2014

Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network

J.M.P.A. van den Reek; P.P.M. van Lümig; M.E. Kooijmans; J. Zweegers; P.C.M. van de Kerkhof; P.M. Ossenkoppele; Njoo; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; B.A.M. Sybrandy-Fleuren; A.L.A. Kuijpers; M.P.M. Andriessen; M.M.B. Seyger; Wietske Kievit; E.M.G.J. de Jong

Although the effectiveness of biologics for psoriasis has been measured extensively with objective outcome measures, studies based on subjective, patient‐reported outcome measures remain scarce.

British Journal of Dermatology | 2017

Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort

J. Zweegers; B. Roosenboom; P.C.M. van de Kerkhof; J.M.P.A. van den Reek; M.E. Otero; S. Atalay; A.L.A. Kuijpers; M.I.A. Koetsier; W.P. Arnold; Berends; L. Weppner-Parren; M. Bijen; Njoo; J.M. Mommers; P.P.M. van Lümig; R.J.B. Driessen; Wietske Kievit; E.M.G.J. de Jong

It is important to assess which patients with psoriasis are more likely to achieve high clinical responses on biologics.

Acta Dermato-venereologica | 1995

Epidermal regeneration and occlusion.

P.C.M. van de Kerkhof; S. de Mare; W.P. Arnold; P.E.J. van Erp

Journal of The American Academy of Dermatology | 1994

Topical capsaicin in pruritic psoriasis

W.P. Arnold; P.C.M. van de Kerkhof

British Journal of Dermatology | 2001

A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxypsoralen baths

W.P. Arnold; P. Van Andel; D. de Hoop; L. De Jong‐Tieben; M. Visser‐van Andel

Journal of The European Academy of Dermatology and Venereology | 1996

A multicentre evaluation of the guidelines for the use of cyclosporin A in severe psoriasis

L. Witkamp; M.M.H.M. Meinardi; P.M.M. Bossuyt; P.C.M. van de Kerkhof; W.P. Arnold; D. de Hoop; F.H.J. Rampen; D.J. Tazelaar; G.R.R. Kuiters; B. Hamminga; R.E. Boelen; W.J.M. Habets; N.Verburgh-Van de Zwan; Jan D. Bos

Explore More